A Phase I Single Arm Dose Escalation Study of the Combination of Dasatinib (Sprycel) With Lenalidomide (Revlimid) and Dexamethasone (Decadron) in Subjects With Relapsed and/ or Refractory Multiple Myeloma.

Trial Profile

A Phase I Single Arm Dose Escalation Study of the Combination of Dasatinib (Sprycel) With Lenalidomide (Revlimid) and Dexamethasone (Decadron) in Subjects With Relapsed and/ or Refractory Multiple Myeloma.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 May 2013

At a glance

  • Drugs Dasatinib; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Nov 2012 Planned end date changed from 1 Jul 2012 to 1 Apr 2013 as reported by ClinicalTrials.gov.
    • 23 Aug 2011 Planned End Date changed from 1 Oct 2011 to 1 Jul 2012 as reported by ClinicalTrials.gov.
    • 11 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top